AXGN
Neutral signalScored 2026-09-08 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
AxoGen, Inc.
- Nom
- AxoGen, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Devices
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 622
- PDG
- Michael D. Dale
- Site web
- https://www.axogeninc.com
- Marché
- BSEMHUMAMDXGORGOTELAXTNT
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 31 003 titres (~1 461 498,52 $ US)
- Insiders
- TYNDALL JOSEPH A.Wendell Amy McBrideWeiler Kathy Johnson
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$4,657,286
Avg sell (VWAP, 90d window) $47.28 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$4,657,286 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-02 | TYNDALL JOSEPH A. | Sell · S · 10b5-1 | 3,500 | $49.70 | $173,940 | Form 4 |
| 2026-08-11 | Wendell Amy McBride | Sell · S · 10b5-1 | 13,353 | $48.42 | $646,592 | Form 4 |
| 2026-08-10 | Began Marc A | Sell · S · 10b5-1 | 67,500 | $47.34 | $3,195,788 | Form 4 |
| 2026-08-07 | Weiler Kathy Johnson | Sell · S · 10b5-1 | 14,150 | $45.30 | $640,967 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
| 2019-04-16 | Donna Shalala | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-08 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
AXGN combines a weak catalyst score (25, NONE type) with deeply concerning fundamentals — persistent net losses, negative interest coverage, and an EV/EBITDA above 8000 — making the 75 liquidity score insufficient to…
The first sentence of the analysis written for AXGN on 2026-09-08 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.7M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.7M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 5.11 · operating margin -3.5% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 74.3% | 75.8% | 76.6% | 78.5% | 82.0% | |
| Ebit Margin | -3.6% | -0.9% | -11.9% | -20.4% | -20.1% | |
| Ebitda Margin | 0.1% | 3.2% | -8.4% | -16.9% | -16.4% | |
| Operating Profit Margin | -3.5% | -1.8% | -13.5% | -21.4% | -20.0% | |
| Pretax Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Continuous Operations Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Net Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Bottom Line Profit Margin | -7.0% | -5.3% | -13.7% | -20.9% | -21.2% | |
| Current Ratio | 5.112 | 3.241 | 2.892 | 4.129 | 5.230 | |
| Quick Ratio | 3.313 | 2.157 | 2.136 | 3.333 | 4.543 | |
| Solvency Ratio | -0.081 | -0.021 | -0.160 | -0.255 | -0.233 | |
| Cash Ratio | 1.509 | 0.900 | 1.020 | 0.643 | 1.348 | |
| Price To Earnings Ratio | -96.265 | -71.652 | -13.392 | -14.464 | -14.415 | |
| Price To Earnings Growth Ratio | -2.013 | 1.305 | 0.513 | -2.350 | -1.730 | |
| Forward Price To Earnings Growth Ratio | -2.013 | 1.305 | 0.513 | -2.350 | -1.730 | |
| Price To Earnings Diluted Ratio | -96.265 | -71.652 | -13.392 | -14.464 | -14.415 | |
| Price To Earnings Diluted Growth Ratio | -2.013 | 1.305 | 0.513 | -2.350 | -1.730 | |
| Price To Book Ratio | 11.698 | 7.019 | 3.061 | 4.158 | 3.431 | |
| Price To Sales Ratio | 6.693 | 3.893 | 1.842 | 3.031 | 3.032 | |
| Price To Free Cash Flow Ratio | -513.885 | 66,306.531 | -14.193 | -11.254 | -9.238 | |
| Price To Operating Cash Flow Ratio | 1,856.189 | 160.832 | -51.235 | -26.142 | -28.809 | |
| Debt To Assets Ratio | 0.305 | 0.337 | 0.352 | 0.345 | 0.324 | |
| Debt To Equity Ratio | 0.525 | 0.661 | 0.724 | 0.668 | 0.599 | |
| Debt To Capital Ratio | 0.344 | 0.398 | 0.420 | 0.400 | 0.375 | |
| Long Term Debt To Capital Ratio | 0.273 | 0.314 | 0.328 | 0.312 | 0.285 | |
| Financial Leverage Ratio | 1.721 | 1.961 | 2.057 | 1.935 | 1.848 | |
| Working Capital Turnover Ratio | 2.722 | 2.969 | 2.411 | 1.565 | 1.131 | |
| Operating Cash Flow Ratio | 0.034 | 0.148 | -0.188 | -0.676 | -0.552 | |
| Operating Cash Flow Sales Ratio | 0.004 | 0.024 | -0.036 | -0.116 | -0.105 | |
| Free Cash Flow Operating Cash Flow Ratio | -3.612 | 0.002 | 3.610 | 2.323 | 3.119 | |
| Debt Service Coverage Ratio | 0.025 | 0.741 | -4.701 | -37.614 | -15.404 | |
| Interest Coverage Ratio | -1.019 | -0.401 | -7.570 | -47.607 | -18.743 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.012 | 0.066 | -0.082 | -0.238 | -0.199 | |
| Capital Expenditure Coverage Ratio | 0.217 | 1.002 | -0.383 | -0.756 | -0.472 | |
| Dividend Paid And Capex Coverage Ratio | 0.217 | 1.002 | -0.383 | -0.756 | -0.472 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 8,017.220 | 126.748 | -24.845 | -20.116 | -20.149 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 74.3% | ▼-1.5% | ▼-3.1% |
| Ebit Margin | -3.5% | ▼-2.6% | ▲7.8% |
| Ebitda Margin | 0.1% | ▼-3.2% | ▲7.8% |
| Operating Profit Margin | -3.5% | ▼-1.7% | ▲8.5% |
| Pretax Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Continuous Operations Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Net Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Bottom Line Profit Margin | -7.0% | ▼-1.7% | ▲6.6% |
| Current Ratio | 5.112 | ▲1.871 | ▲0.991 |
| Quick Ratio | 3.313 | ▲1.156 | ▲0.217 |
| Solvency Ratio | -0.081 | ▼-0.060 | ▲0.069 |
| Cash Ratio | 1.509 | ▲0.609 | ▲0.425 |
| Price To Earnings Ratio | -96.265 | ▼-24.613 | ▼-54.227 |
| Price To Earnings Growth Ratio | -2.013 | ▼-3.318 | ▼-1.158 |
| Forward Price To Earnings Growth Ratio | -2.013 | ▼-3.318 | ▼-1.158 |
| Price To Earnings Diluted Ratio | -96.265 | ▼-24.613 | ▼-54.227 |
| Price To Earnings Diluted Growth Ratio | -2.013 | ▼-3.318 | ▼-1.158 |
| Price To Book Ratio | 11.698 | ▲4.678 | ▲5.824 |
| Price To Sales Ratio | 6.693 | ▲2.799 | ▲2.994 |
| Price To Free Cash Flow Ratio | -513.885 | ▼-66820.416 | ▼-13665.477 |
| Price To Operating Cash Flow Ratio | 1856.189 | ▲1695.357 | ▲1474.022 |
| Debt To Assets Ratio | 0.305 | ▼-0.032 | ▼-0.028 |
| Debt To Equity Ratio | 0.525 | ▼-0.136 | ▼-0.111 |
| Debt To Capital Ratio | 0.344 | ▼-0.054 | ▼-0.043 |
| Long Term Debt To Capital Ratio | 0.273 | ▼-0.041 | ▼-0.029 |
| Financial Leverage Ratio | 1.720 | ▼-0.240 | ▼-0.184 |
| Working Capital Turnover Ratio | 2.722 | ▼-0.247 | ▲0.562 |
| Operating Cash Flow Ratio | 0.035 | ▼-0.114 | ▲0.281 |
| Operating Cash Flow Sales Ratio | 0.004 | ▼-0.021 | ▲0.050 |
| Free Cash Flow Operating Cash Flow Ratio | -3.612 | ▼-3.615 | ▼-4.700 |
| Debt Service Coverage Ratio | 0.025 | ▼-0.716 | ▲11.416 |
| Interest Coverage Ratio | -1.019 | ▼-0.619 | ▲14.049 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.012 | ▼-0.054 | ▲0.100 |
| Capital Expenditure Coverage Ratio | 0.217 | ▼-0.786 | ▲0.295 |
| Dividend Paid And Capex Coverage Ratio | 0.217 | ▼-0.786 | ▲0.295 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 8017.220 | ▲7890.471 | ▲6401.448 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.51B | $729.4M | $292.9M | $420.0M | $386.2M | |
| Enterprise value | $1.54B | $770.5M | $331.1M | $472.1M | $420.9M | |
| EV / Sales | 6.83x | 4.11x | 2.08x | 3.41x | 3.31x | |
| EV / Op. cash flow | 1895.70x | 169.90x | -57.93x | -29.39x | -31.40x | |
| EV / Free cash flow | -524.82x | 70045.80x | -16.05x | -12.65x | -10.07x | |
| EV / EBITDA | 8017.22x | 126.75x | -24.84x | -20.12x | -20.15x | |
| Net debt / EBITDA | 167.09x | 6.77x | -2.87x | -2.22x | -1.66x | |
| Current ratio | 5.11x | 3.24x | 2.89x | 4.13x | 5.23x | |
| Income quality | -0.05x | -0.46x | 0.26x | 0.56x | 0.50x | |
| Graham net-net | -$0 | -$1 | -$1 | -$0 | $0 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 196.3% | 566.8% | 115.0% | 102.2% | 105.3% | |
| Working capital | $96.9M | $68.6M | $57.6M | $74.3M | $102.8M | |
| Invested capital | $198.1M | $173.1M | $166.4M | $171.6M | $183.7M | |
| Return on assets | -7.1% | -4.9% | -11.0% | -14.8% | -13.0% | |
| Operating ROA | -3.7% | -1.6% | -10.9% | -14.7% | -12.4% | |
| Return on tangible assets | -7.3% | -5.0% | -11.3% | -15.1% | -13.2% | |
| Return on equity | -12.2% | -9.6% | -22.7% | -28.7% | -24.0% | |
| Return on invested capital | -3.9% | -1.9% | -12.8% | -17.2% | -13.7% | |
| Return on capital employed | -4.0% | -1.9% | -12.9% | -17.3% | -13.8% | |
| Earnings yield | -1.0% | -1.4% | -7.4% | -6.9% | -7.0% | |
| Free cash flow yield | -0.2% | 0.0% | -7.0% | -8.9% | -10.8% | |
| Capex / Op. cash flow | 461.2% | 99.8% | -261.0% | -132.3% | -211.9% | |
| Capex / Depreciation | 45.7% | 57.7% | 268.6% | 437.9% | 599.0% | |
| Capex / Sales | 1.7% | 2.4% | 9.4% | 15.3% | 22.3% | |
| SG&A / Sales | 63.2% | 62.7% | 72.9% | 81.5% | 83.0% | |
| R&D / Sales | 14.6% | 14.8% | 17.2% | 18.5% | 19.0% | |
| Stock comp / Sales | 13.4% | 8.5% | 9.1% | 11.3% | 8.6% | |
| Intangibles / Total assets | 3.0% | 2.7% | 2.3% | 1.9% | 1.4% | |
| Days sales outstanding | 42d | 47d | 58d | 58d | 52d | |
| Days payables outstanding | 18d | 64d | 116d | 110d | 94d | |
| Operating cycle | 310d | 314d | 284d | 290d | 318d | |
| Cash conversion cycle | 292d | 250d | 168d | 180d | 223d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-01 Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference ALACHUA, Fla. and TAMPA, Fla.
- 2026-08-26 Axogen Inc (AXGN) Stock Up 3.3% but GF Value Says Overvalued -- GF Score: 64/100 On August 26, 2026, Axogen Inc (AXGN) shares rose 3.3% to a current price of $51.58, continuing a strong upward trend. Over the past year, the stock has surged
- 2026-08-26 Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly covered before the opening bell Wednesday.
- 2026-08-03 Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underpinned by FDA approval, stronger reimbursement, and expanding clinical evidence. Q2 2026 revenue grew 23.1% to $69.7M, with raised full-year guidance and strong elective market traction, though gross margin declined due to product mix and biologic costs. Avance''s FDA biologic approval grants 12 years of exclusivity, regulatory credibility, and improved payer coverage, positioning AXGN as a category leader with significant market opportunity.
- 2026-07-30 AxoGen (NASDAQ:AXGN) Shares Gap Down Following Weak Earnings AxoGen, Inc. (NASDAQ: AXGN - Get Free Report)''s stock price gapped down prior to trading on Wednesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $41.15, but opened at $38.31. AxoGen shares last traded at $44.5120, with a volume of 317,776 shares trading hands. The medical equipment provider reported
- 2026-07-29 Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript
- 2026-07-29 AxoGen Q2 Earnings Call Highlights AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing growth of at least 24%, while lowering its gross-margin expectation to at least 73% due to product-mix changes tied to faster-than-expected growth in breast reconstruction.
- 2026-07-29 AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.
- 2026-07-29 Trace Biosciences Announces Strategic Investment from Axogen to Advance Clinical Development of its Nerve Trace Nerve-Specific Imaging Technology /PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-targeted imaging agents, today announced it has received a
- 2026-07-29 Axogen, Inc. Reports Second Quarter 2026 Financial Results ALACHUA, Fla. and TAMPA, Fla.